Mineralocorticoid antagonists in chronic kidney disease.

@article{Dhaybi2017MineralocorticoidAI,
  title={Mineralocorticoid antagonists in chronic kidney disease.},
  author={Omar Al Dhaybi and George C Bakris},
  journal={Current opinion in nephrology and hypertension},
  year={2017},
  volume={26 1},
  pages={50-55}
}
PURPOSE OF REVIEW Current evidence showcases the pathologic effects of excess aldosterone in promoting glomerular and tubulointerstitial inflammation and fibrosis through various pathways. The place for mineralocorticoid receptor antagonists (MRAs) in chronic kidney disease (CKD) progression is unclear. RECENT FINDINGS MRAs further reduce albuminuria and… CONTINUE READING